Skip to main content
. 2024 Jun 3;15:1414268. doi: 10.3389/fphar.2024.1414268

FIGURE 1.

FIGURE 1

The process of screening semaglutide from the Food and Drug Administration adverse event reporting database for adverse events associated with different routes of administration.